Paliperidone Palmitate Once-Monthly Injectable Treatment for Acute Exacerbations of Schizoaffective Disorder.

Abstract:

:The optimal treatment for schizoaffective disorder (SCA) is not well established. In this initial 6-month open-label treatment period of a large, multiphase, relapse-prevention study, the efficacy and safety of paliperidone palmitate once-monthly (PP1M) injectable were evaluated in subjects with symptomatic SCA. Subjects with acute exacerbation of SCA (ie, with psychotic and either depressive and/or manic symptoms) were enrolled and treated with PP1M either as monotherapy or in combination with antidepressants or mood stabilizers (combination therapy group). After flexible-dose treatment with PP1M for 13 weeks, stabilized subjects continued into a 12-week fixed-dose PP1M treatment period. A total of 667 subjects were enrolled; 320 received monotherapy and 347 received PP1M as combination therapy; 334 subjects completed the entire 25-week treatment. Statistically significant and clinically meaningful improvements from baseline were observed for all efficacy measures in psychosis (per Positive and Negative Syndrome Scale), mood symptoms (per Young Mania Rating Scale and Hamilton Depression Rating Scale-21 items), and functioning (per Personal and Social Performance Scale) from week 1 to all time points during the 25-week treatment period (P < 0.001). Similar improvements in efficacy measures were observed between subjects receiving monotherapy or combination therapy. Efficacy benefits persisted throughout the 25-week period. The most common adverse events were akathisia (11.1%), injection-site pain (10.6%), and insomnia (10.0%). Paliperidone palmitate once-monthly administered as monotherapy or in combination with mood stabilizers or antidepressants in patients with an acute exacerbation of SCA provided rapid, broad, and persistent reduction in psychotic, depressive, and manic symptoms, as well as improved functioning.

journal_name

J Clin Psychopharmacol

authors

Fu DJ,Turkoz I,Simonson RB,Walling D,Schooler N,Lindenmayer JP,Canuso C,Alphs L

doi

10.1097/JCP.0000000000000535

subject

Has Abstract

pub_date

2016-08-01 00:00:00

pages

372-6

issue

4

eissn

0271-0749

issn

1533-712X

journal_volume

36

pub_type

杂志文章
  • Quetiapine for treatment of alcohol dependence.

    abstract::Quetiapine is an atypical antipsychotic that has sedative effects. In this retrospective study, indices of alcohol use were compared for alcohol-dependent subjects who either were (n = 30) or were not (n = 20) treated with quetiapine (25 to 200 mg nightly) for disturbed sleep. Indices examined included total days of a...

    journal_title:Journal of clinical psychopharmacology

    pub_type: 杂志文章

    doi:10.1097/01.jcp.0000138763.23482.2a

    authors: Monnelly EP,Ciraulo DA,Knapp C,LoCastro J,Sepulveda I

    更新日期:2004-10-01 00:00:00

  • A single-center, cross-sectional prevalence study of impulse control disorders in Parkinson disease: association with dopaminergic drugs.

    abstract::The current study aimed at establishing the prevalence of impulse control disorders (ICDs) in patients with Parkinson disease (PD) and their association with demographic, drug-related, and disease-related characteristics. We performed a single-center cross-sectional study of 805 PD patients. Impulse control disorders ...

    journal_title:Journal of clinical psychopharmacology

    pub_type: 杂志文章

    doi:10.1097/JCP.0b013e3182979830

    authors: Poletti M,Logi C,Lucetti C,Del Dotto P,Baldacci F,Vergallo A,Ulivi M,Del Sarto S,Rossi G,Ceravolo R,Bonuccelli U

    更新日期:2013-10-01 00:00:00

  • Effect of Rivastigmine Augmentation in Treatment of Male Patients With Combat-Related Chronic Posttraumatic Stress Disorder: A Randomized Controlled Trial.

    abstract:BACKGROUND:Posttraumatic stress disorder (PTSD) is one of the chronic and disabling psychiatric disorders, particularly in combat veterans. In a case series, rivastigmine was suggested to be an effective augmentation in treatment of PTSD. The aim of the present study was to evaluate this finding in a randomized control...

    journal_title:Journal of clinical psychopharmacology

    pub_type: 杂志文章,随机对照试验

    doi:10.1097/JCP.0000000000000624

    authors: Rezaei Ardani A,Hosseini G,Fayyazi Bordbar MR,Talaei A,Mostafavi Toroghi H

    更新日期:2017-02-01 00:00:00

  • Duration of imipramine therapy and relapse in panic disorder with agoraphobia.

    abstract::It has been suggested that maintenance treatment of patients who have remitted panic disorder with agoraphobia beyond the six months of acute phase imipramine treatment may decrease the risk of relapse. This study further explores the relationship between relapse and duration of imipramine treatment in this population...

    journal_title:Journal of clinical psychopharmacology

    pub_type: 临床试验,杂志文章,随机对照试验

    doi:10.1097/00004714-200206000-00010

    authors: Mavissakalian MR,Perel JM

    更新日期:2002-06-01 00:00:00

  • Prescription patterns of psychotropic medications for the treatment of psychotic disorders in the largest mental health institutions of Uganda.

    abstract::The study describes prescription patterns of psychotropic medications for patients treated for psychosis in psychiatric hospitals of Uganda. A cross-sectional quantitative survey of age, sex, diagnoses, and psychotropic medication of 682 psychiatric inpatients of the 2 national referral hospitals in Uganda was conduct...

    journal_title:Journal of clinical psychopharmacology

    pub_type: 杂志文章

    doi:10.1097/JCP.0000000000000166

    authors: Rukat A,Musisi S,Ströhle A,Mundt AP

    更新日期:2014-10-01 00:00:00

  • The 2-mg dexamethasone suppression test in differentiating major depression with psychosis from schizophrenia.

    abstract::The 2-mg dexamethasone suppression test (DST), performed in a drug-free acute exacerbation phase of illness shortly after admission, differentiated between major depression with psychosis and stringently diagnosed chronic schizophrenia. This has practical significance because effective drug treatment in each diagnosti...

    journal_title:Journal of clinical psychopharmacology

    pub_type: 杂志文章

    doi:

    authors: Clower CG

    更新日期:1986-12-01 00:00:00

  • Exposure to anticholinergic and sedative drugs, risk of falls, and mortality: an elderly inpatient, multicenter cohort.

    abstract::This study aimed to assess whether exposure to anticholinergic and sedative medications and its evolution was associated with increased risk of in-hospital falls and all-cause mortality. Furthermore, results were compared with 2 definitions of drug burden index (DBI) against the outcomes.This observational, multicentr...

    journal_title:Journal of clinical psychopharmacology

    pub_type: 杂志文章,多中心研究

    doi:10.1097/JCP.0000000000000195

    authors: Dauphinot V,Faure R,Omrani S,Goutelle S,Bourguignon L,Krolak-Salmon P,Mouchoux C

    更新日期:2014-10-01 00:00:00

  • Assessment of Drug-Associated Extrapyramidal Symptoms in People With Intellectual Disability: A Comparison of an Informant-Based Scale With Clinical Rating Scales.

    abstract::Drug-associated extrapyramidal symptoms (EPS) in people with intellectual disability (ID) may be difficult to recognize, and clinicians' assessments may be hampered by lack of patients' capacities to adequately cooperate and by lack of reliable instruments to measure EPS in this population. Therefore, we compared asse...

    journal_title:Journal of clinical psychopharmacology

    pub_type: 杂志文章

    doi:10.1097/JCP.0000000000000558

    authors: de Kuijper GM,Hoekstra PJ

    更新日期:2016-10-01 00:00:00

  • Quetiapine versus placebo in combination with lithium or divalproex for the treatment of bipolar mania.

    abstract::Quetiapine (QTP) combined with lithium (Li) or divalproex (DVP) for the treatment of mania was evaluated in 2 double-blind, placebo-controlled studies. Patients were randomized to 3 or 6 weeks of treatment with QTP plus Li/DVP or placebo (PBO) plus Li/DVP. Quetiapine was dosed up to 800 mg/d; Li was dosed to achieve s...

    journal_title:Journal of clinical psychopharmacology

    pub_type: 临床试验,杂志文章,随机对照试验

    doi:10.1097/01.jcp.0000144887.66319.2f

    authors: Yatham LN,Paulsson B,Mullen J,Vågerö AM

    更新日期:2004-12-01 00:00:00

  • Drug studies in women of childbearing age: ethical and methodological considerations.

    abstract::Despite a recognized need for the inclusion of women of childbearing age in drug studies, many such studies include only men. This practice is due mainly to the added risk of teratogenicity and to cyclic variations in the menstrual phase and hormonal state. The methodological and ethical problems associated with drug ...

    journal_title:Journal of clinical psychopharmacology

    pub_type: 杂志文章,评审

    doi:

    authors: Halbreich U,Carson SW

    更新日期:1989-10-01 00:00:00

  • Hospitalization resource utilization and costs among Medicaid insured patients with schizophrenia with different treatment durations of long-acting injectable antipsychotic therapy.

    abstract::This study evaluated the impact of using long-acting injectable (LAI) antipsychotics for a longer treatment duration versus a short duration on health care resource utilization among Medicaid-insured schizophrenia patients. Schizophrenia patients 13 years or older initiating LAI antipsychotics were identified from the...

    journal_title:Journal of clinical psychopharmacology

    pub_type: 杂志文章

    doi:10.1097/JCP.0b013e3182a6082a

    authors: Bera R,Offord S,Zubek D,Lau G,Lin J,Karson C

    更新日期:2014-02-01 00:00:00

  • Efficacy and safety of venlafaxine in the treatment of bipolar II major depressive episode.

    abstract::As many as 45% of patients with major depression also meet diagnostic criteria for bipolar (BP) II disorder. Although the use of a concurrent mood-stabilizing drug has been suggested in treating BP II depression, antidepressant monotherapy has received less attention. The efficacy and safety of venlafaxine were examin...

    journal_title:Journal of clinical psychopharmacology

    pub_type: 临床试验,杂志文章,随机对照试验

    doi:10.1097/00004714-199810000-00010

    authors: Amsterdam J

    更新日期:1998-10-01 00:00:00

  • Description of the Treatment Course by Pregabalin for Anxiety in Patients With a Major Neurocognitive Disorder.

    abstract:BACKGROUND:Anxiety symptoms frequently experienced by patients with a major neurocognitive disorder (NCD) are often treated with long-term benzodiazepines despite known adverse effects. Pregabalin has shown efficacy in generalized anxiety disorders but has not been studied in patients with a major NCD. The objective of...

    journal_title:Journal of clinical psychopharmacology

    pub_type: 杂志文章

    doi:10.1097/JCP.0000000000001029

    authors: Novais T,Doutone A,Gombault C,Krolak-Salmon P,Lepetit A,Mouchoux C

    更新日期:2019-05-01 00:00:00

  • Association between HTR2C and HTR2A polymorphisms and metabolic abnormalities in patients treated with olanzapine or clozapine.

    abstract::Serotonin 2C and 2A receptor (5-HT2C and 5-HT2A) antagonisms are hypothesized to play a role in the metabolic adverse effects induced by olanzapine and clozapine. Associations between polymorphisms in 5-HT2C and 5-HT2A receptor coding genes, HTR2C and HTR2A, with antipsychotic-induced weight gain have been reported. T...

    journal_title:Journal of clinical psychopharmacology

    pub_type: 杂志文章

    doi:10.1097/JCP.0b013e31819302c3

    authors: Gunes A,Melkersson KI,Scordo MG,Dahl ML

    更新日期:2009-02-01 00:00:00

  • Methamphetamine self-administration in humans during D-amphetamine maintenance.

    abstract::Agonist replacement may be a viable treatment approach for managing stimulant use disorders. This study sought to determine the effects of D-amphetamine maintenance on methamphetamine self-administration in stimulant using human participants. We predicted that D-amphetamine maintenance would reduce methamphetamine sel...

    journal_title:Journal of clinical psychopharmacology

    pub_type: 杂志文章

    doi:10.1097/JCP.0000000000000207

    authors: Pike E,Stoops WW,Hays LR,Glaser PE,Rush CR

    更新日期:2014-12-01 00:00:00

  • Trends in the adoption of medications for alcohol dependence.

    abstract::Increasing attention is being paid to the development and dissemination of effective pharmacotherapies for the treatment of alcohol and other drug dependence. However, numerous structural and philosophical barriers impede the widespread adoption of these treatment approaches in everyday clinical practice. Research is ...

    journal_title:Journal of clinical psychopharmacology

    pub_type: 杂志文章,meta分析,评审

    doi:10.1097/01.jcp.0000246209.18777.14

    authors: Ducharme LJ,Knudsen HK,Roman PM

    更新日期:2006-12-01 00:00:00

  • A Phase 2 Randomized Dose-Finding Study With Esmirtazapine in Patients With Primary Insomnia.

    abstract::The antidepressant mirtazapine is an alternative to classical hypnotics, and this study investigated the efficacy and safety of esmirtazapine (Org 50081, the maleic acid salt of S-mirtazapine) in patients given a diagnosis of primary insomnia after acute (2-day) treatment. Patients aged 18 to 65 years with primary ins...

    journal_title:Journal of clinical psychopharmacology

    pub_type: 杂志文章,多中心研究,随机对照试验

    doi:10.1097/JCP.0000000000000546

    authors: Ruwe F,IJzerman-Boon P,Roth T,Zammit G,Ivgy-May N

    更新日期:2016-10-01 00:00:00

  • Amoxapine versus amitriptyline for continuation therapy of depression.

    abstract::The efficacy of continuation therapy with tricyclic antidepressants has been established in a number of controlled trials. This study investigated the efficacy of continuation therapy with a relatively new antidepressant, amoxapine, using a double-blind controlled comparison with amitriptyline. Subjects met DSM-III cr...

    journal_title:Journal of clinical psychopharmacology

    pub_type: 临床试验,杂志文章,随机对照试验

    doi:

    authors: Mason BJ,Kocsis JH,Frances AJ,Mann JJ

    更新日期:1990-10-01 00:00:00

  • Effects of aripiprazole and the Taq1A polymorphism in the dopamine D2 receptor gene on the clinical response and plasma monoamine metabolites level during the acute phase of schizophrenia.

    abstract::The Taq1A polymorphism in the dopamine D2 receptor (DRD2) gene could be related to the response to antipsychotics. We examined the effects of the Taq1A polymorphism on the plasma monoamine metabolites during the treatment of schizophrenia with aripiprazole, a DRD2 partial agonist. Thirty Japanese patients with schizop...

    journal_title:Journal of clinical psychopharmacology

    pub_type: 临床试验,杂志文章

    doi:10.1097/JCP.0b013e31823f87ac

    authors: Miura I,Takeuchi S,Katsumi A,Mori A,Kanno K,Yang Q,Mashiko H,Numata Y,Niwa S

    更新日期:2012-02-01 00:00:00

  • No difference in brain activation during cognitive performance between ecstasy (3,4-methylenedioxymethamphetamine) users and control subjects: a [H2(15)O]-positron emission tomography study.

    abstract::The long-term use of the serotonin-releaser and uptake-inhibitor 3,4-methylenedioxymethamphetamine (MDMA, "Ecstasy") has been associated with memory impairments and increased liability to depressive mood and anxiety attacks. It is unclear, however, whether these psychologic deviations are reflected in alterations of t...

    journal_title:Journal of clinical psychopharmacology

    pub_type: 杂志文章

    doi:10.1097/00004714-200102000-00012

    authors: Gamma A,Buck A,Berthold T,Vollenweider FX

    更新日期:2001-02-01 00:00:00

  • A comparison study of multiple measures of adherence to antipsychotic medication in first-episode psychosis.

    abstract::This study evaluates how much agreement there is between subjective reports of adherence to antipsychotic medication and objective or derived measures of adherence in first-episode psychosis (FEP) and asks if any adherence measure could approximate a gold standard based on correlation to symptom improvement in the ear...

    journal_title:Journal of clinical psychopharmacology

    pub_type: 杂志文章

    doi:10.1097/JCP.0b013e3181ca03df

    authors: Cassidy CM,Rabinovitch M,Schmitz N,Joober R,Malla A

    更新日期:2010-02-01 00:00:00

  • Double-blind clinical trial of sertraline treatment for alcohol dependence.

    abstract::Clinical studies that have evaluated serotonergic medications to reduce alcohol consumption have yielded conflicting results. These studies primarily treated patients with alcohol dependence, excluding those with a current depressive disorder, in an effort to differentiate any medication effects directly on drinking f...

    journal_title:Journal of clinical psychopharmacology

    pub_type: 临床试验,杂志文章,随机对照试验

    doi:10.1097/00004714-200104000-00005

    authors: Pettinati HM,Volpicelli JR,Luck G,Kranzler HR,Rukstalis MR,Cnaan A

    更新日期:2001-04-01 00:00:00

  • Characterizing anticholinergic abuse in community mental health.

    abstract::To identify factors associated with anticholinergic abuse in patients taking antipsychotics and anticholinergics and to document the extent of extrapyramidal side effects in anticholinergic abusers, 21 anticholinergic abusers were matched with 21 controls without a history of anticholinergic abuse for diagnosis and an...

    journal_title:Journal of clinical psychopharmacology

    pub_type: 杂志文章

    doi:

    authors: Wells BG,Marken PA,Rickman LA,Brown CS,Hamann G,Grimmig J

    更新日期:1989-12-01 00:00:00

  • Tricyclic-induced electroencephalogram abnormalities and plasma drug concentrations.

    abstract::In a double-blind study of 34 randomly assigned depressed inpatients, antidepressant-induced electroencephalogram (EEG) abnormalities were compared in amitriptyline-treated versus bupropion-treated patients. Drug-free baseline EEGs plus one or more repeat EEGs under pharmacokinetic steady state conditions were obtaine...

    journal_title:Journal of clinical psychopharmacology

    pub_type: 临床试验,杂志文章,随机对照试验

    doi:

    authors: Preskorn SH,Othmer SC,Lai CW,Othmer E

    更新日期:1984-10-01 00:00:00

  • Lithium poisoning: pharmacokinetics and clearance during different therapeutic measures.

    abstract::The clinical features and pharmacokinetics of 22 lithium overdoses are described. Effectiveness of different treatment regimens regarding elimination of lithium is discussed. Origin of overdose was due to deliberate poisoning or precipitated by concomitant diseases, coadministration of drugs, or combination of both. T...

    journal_title:Journal of clinical psychopharmacology

    pub_type: 杂志文章

    doi:10.1097/01.jcp.0000218405.02738.b3

    authors: Eyer F,Pfab R,Felgenhauer N,Lutz J,Heemann U,Steimer W,Zondler S,Fichtl B,Zilker T

    更新日期:2006-06-01 00:00:00

  • Disposition of haloperidol pyridinium and reduced haloperidol pyridinium in schizophrenic patients: no relationship with clinical variables during short-term treatment.

    abstract::In an open clinical trial, serum concentrations of haloperidol pyridinium (C(HP+)) and reduced haloperidol pyridinium (C(RHP+)), as well as haloperidol (CH) and reduced haloperidol (C(RH)), were measured in 57 schizophrenic and schizoaffective inpatients during 6 weeks of short-term treatment. Psychopathology was moni...

    journal_title:Journal of clinical psychopharmacology

    pub_type: 临床试验,杂志文章

    doi:10.1097/00004714-200004000-00014

    authors: Ulrich S,Neuhof S,Braun V,Danos P,Pester U,Hoy L

    更新日期:2000-04-01 00:00:00

  • Long-term efficacy and safety of iloperidone: results from 3 clinical trials for the treatment of schizophrenia.

    abstract::This research compared the long-term efficacy and safety of iloperidone with those of haloperidol in individuals with schizophrenia. Data were pooled from 3 prospective multicenter studies, each with 6-week stabilization followed by 46-week double-blind maintenance phases. Patients were randomized to iloperidone 4 to ...

    journal_title:Journal of clinical psychopharmacology

    pub_type: 杂志文章,meta分析

    doi:10.1097/JCP.0b013e318169cca7

    authors: Kane JM,Lauriello J,Laska E,Di Marino M,Wolfgang CD

    更新日期:2008-04-01 00:00:00

  • Pharmacokinetic and pharmacodynamic evaluation of the inhibition of alprazolam by citalopram and fluoxetine.

    abstract::The selective serotonin reuptake inhibitor antidepressant fluoxetine inhibits alprazolam metabolism in vivo by inhibition of the cytochrome P450 3A4 enzyme. Citalopram is a selective serotonin reuptake inhibitor antidepressant that has not yet been fully evaluated with respect to its potential for cytochrome P450 3A4-...

    journal_title:Journal of clinical psychopharmacology

    pub_type: 临床试验,杂志文章,随机对照试验

    doi:10.1097/01.jcp.0000085407.08426.e1

    authors: Hall J,Naranjo CA,Sproule BA,Herrmann N

    更新日期:2003-08-01 00:00:00

  • Psychological strategies for discontinuing benzodiazepine treatment.

    abstract::Successful discontinuation of therapeutic drugs requires patients to negotiate two potentially difficult phases. First, they must complete the drug discontinuation procedure itself, which may entail coping with rebound and withdrawal symptoms as well as anxiety due to stopping a treatment on which they depend psycholo...

    journal_title:Journal of clinical psychopharmacology

    pub_type: 杂志文章,评审

    doi:10.1097/00004714-199912002-00004

    authors: Spiegel DA

    更新日期:1999-12-01 00:00:00

  • DRD2 Taq1A polymorphism modulates prolactin secretion induced by atypical antipsychotics in healthy volunteers.

    abstract::Hyperprolactinemia mediated by antagonism of dopaminergic neurotransmission in the pituitary gland is a common adverse effect of antipsychotics. Recent studies have suggested that polymorphisms of dopamine receptors can affect the therapeutic response to antipsychotics. Thus, our aim was to evaluate whether 2 such pol...

    journal_title:Journal of clinical psychopharmacology

    pub_type: 杂志文章

    doi:10.1097/JCP.0b013e31822cfff2

    authors: López-Rodríguez R,Román M,Novalbos J,Pelegrina ML,Ochoa D,Abad-Santos F

    更新日期:2011-10-01 00:00:00